Paolo Verderio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6812529/publications.pdf

Version: 2024-02-01

142 papers 3,683 citations

32 h-index 54 g-index

144 all docs

144 docs citations

times ranked

144

5969 citing authors

#	Article	IF	CITATIONS
1	Cytotoxicity of some catalysts commonly used in the synthesis of copolymers for biomedical use. Journal of Materials Science: Materials in Medicine, 1994, 5, 393-396.	1.7	189
2	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Journal of Clinical Oncology, 2012, 30, 850-856.	0.8	156
3	Evaluation of SNPs in <i>miR-146a</i> , <i>miR196a2</i> and <i>miR-499</i> as low-penetrance alleles in German and Italian familial breast cancer cases. Human Mutation, 2010, 31, E1052-E1057.	1.1	147
4	Effects of Prolonged Storage of Whole Plasma or Isolated Plasma DNA on the Results of Circulating DNA Quantification Assays. Journal of the National Cancer Institute, 2005, 97, 1848-1850.	3.0	144
5	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. European Journal of Cancer, 2019, 109, 51-60.	1.3	134
6	miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. Molecular Cancer Research, 2012, 10, 504-515.	1.5	123
7	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. British Journal of Cancer, 2014, 110, 1001-1007.	2.9	118
8	Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas., 1996, 69, 205-211.		115
9	Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma? results of a multiparametric study. Breast Cancer Research and Treatment, 1995, 36, 205-217.	1.1	102
10	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
11	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology, 2016, 27, 2283-2288.	0.6	90
12	Tumor response assessment by modified Choi criteria in localized highâ€risk soft tissue sarcoma treated with chemotherapy. Cancer, 2012, 118, 5857-5866.	2.0	85
13	Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. International Journal of Cancer, 1994, 57, 822-829.	2.3	75
14	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Annals of Oncology, 2013, 24, 817-823.	0.6	69
15	Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1935-42.	1.4	69
16	67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. International Journal of Cancer, 1995, 60, 604-610.	2.3	65
17	Multiparametric Analysis of Cell-Free DNA in Melanoma Patients. PLoS ONE, 2012, 7, e49843.	1.1	60
18	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. Journal of Clinical Oncology, 2015, 33, 3628-3634.	0.8	59

#	Article	IF	CITATIONS
19	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Annals of Oncology, 2014, 25, 352-357.	0.6	53
20	A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncology Letters, 2017, 13, 315-320.	0.8	52
21	Identification of fifteen novel germline variants in the <i>BRCA1</i> 3′UTR reveals a variant in a breast cancer case that introduces a functional <i>miR-103</i> target site. Human Mutation, 2012, 33, 1665-1675.	1.1	49
22	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of Cancer, 2018, 93, 28-36.	1.3	49
23	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	1.1	44
24	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clinical Cancer Research, 2019, 25, 3887-3895.	3.2	42
25	EQUAL-quant: An International External Quality Assessment Scheme for Real-Time PCR. Clinical Chemistry, 2006, 52, 1584-1591.	1.5	39
26	Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists. Journal of Molecular Diagnostics, 2008, 10, 527-536.	1.2	39
27	SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. Methods, 2013, 59, 20-31.	1.9	39
28	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. Tumori, 2014, 100, 115-121.	0.6	39
29	Chronic Hepatitis C and Interferon Alpha: Conventional and Cumulative Meta-Analyses of Randomized Controlled Trials. American Journal of Gastroenterology, 1999, 94, 581-595.	0.2	38
30	PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Research and Treatment, 2011, 126, 825-828.	1.1	37
31	Plasma miRNAâ€based signatures in CRC screening programs. International Journal of Cancer, 2020, 146, 1164-1173.	2.3	35
32	Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. American Journal of Gastroenterology, 1999, 94, 581-595.	0.2	34
33	SPIDIA-RNA: Second External Quality Assessment for the Pre-Analytical Phase of Blood Samples Used for RNA Based Analyses. PLoS ONE, 2014, 9, e112293.	1.1	33
34	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal of Molecular Sciences, 2020, 21, 1386.	1.8	33
35	SPIDIA-DNA: An External Quality Assessment for the pre-analytical phase of blood samples used for DNA-based analyses. Clinica Chimica Acta, 2013, 424, 274-286.	0.5	30
36	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget, 2014, 5, 4516-4528.	0.8	29

#	Article	IF	CITATIONS
37	Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients International Journal of Oncology, 1998, 12, 1117-25.	1.4	28
38	The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Research and Treatment, 2012, 133, 805-807.	1.1	28
39	Genomic profiling by wholeâ€genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes Chromosomes and Cancer, 2012, 51, 644-653.	1.5	28
40	βâ€Catenin in desmoidâ€ŧype fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Molecular Oncology, 2017, 11, 1495-1507.	2.1	28
41	EQUAL-qual: A European Program for External Quality Assessment of Genomic DNA Extraction and PCR Amplification. Clinical Chemistry, 2007, 53, 1349-1357.	1.5	27
42	Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. International Journal of Molecular Sciences, 2017, 18, 410.	1.8	27
43	Circulating free DNA in a screening program for early colorectal cancer detection. Tumori, 2014, 100, 115-21.	0.6	27
44	Reproducibility of a Semiquantitative Measurement of Circulating DNA in Plasma From Neoplastic Patients. Journal of Clinical Oncology, 2005, 23, 3163-3164.	0.8	26
45	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. Genetics in Medicine, 2014, 16, 688-694.	1.1	25
46	Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 509-519.	1.4	24
47	Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget, 2017, 8, 46177-46190.	0.8	24
48	An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1244-50.	1.4	23
49	SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis, 2009, 30, 544-545.	1.3	23
50	Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Review of Proteomics, 2015, 12, 695-701.	1.3	23
51	Influence of pre-analytical procedures on genomic DNA integrity in blood samples: The SPIDIA experience. Clinica Chimica Acta, 2015, 440, 205-210.	0.5	22
52	In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 45-50.	1.4	22
53	Developing miRNA signatures: a multivariate prospective. British Journal of Cancer, 2016, 115, 1-4.	2.9	22
54	Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. Cancers, 2019, 11, 58.	1.7	22

#	Article	IF	Citations
55	Combined sequential approach in locally advanced breast cancer. Annals of Oncology, 1999, 10, 305-310.	0.6	21
56	The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detection and Prevention, 2008, 32, 140-143.	2.1	20
57	Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Research and Treatment, 2009, 113, 607-608.	1.1	20
58	Effects of Transport and Storage Conditions on Gene Expression in Blood Samples. Biopreservation and Biobanking, 2016, 14, 122-128.	0.5	20
59	An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Manâ,,¢ probes. Clinical Chemistry and Laboratory Medicine, 2005, 43, 542-8.	1.4	19
60	Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Research and Treatment, 1996, 37, 123-133.	1.1	18
61	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers, 2019, 11, 223.	1.7	18
62	Prevalidation of the Rat CFU-GM Assay for In Vitro Toxicology Applications. ATLA Alternatives To Laboratory Animals, 2010, 38, 105-117.	0.7	17
63	Implementation of a proficiency testing for the assessment of the preanalytical phase of blood samples used for RNA based analysis. Clinica Chimica Acta, 2012, 413, 779-786.	0.5	17
64	Biomarkers for Monitoring Pre-Analytical Quality Variation of mRNA in Blood Samples. PLoS ONE, 2014, 9, e111644.	1.1	17
65	Short- and long-term effects of a training session on pathologists' performance: the INQAT experience for histological grading in breast cancer. Journal of Clinical Pathology, 2009, 62, 279-281.	1.0	16
66	NqA: An R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data. Analytical Biochemistry, 2014, 461, 7-9.	1.1	15
67	In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. Human Pathology, 2018, 74, 32-42.	1.1	15
68	Second SPIDIA-DNA External Quality Assessment (EQA): Influence of pre-analytical phase of blood samples on genomic DNA quality. Clinica Chimica Acta, 2016, 454, 10-14.	0.5	14
69	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. Disease Markers, 2017, 2017, 1-11.	0.6	13
70	PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 85-93.	1.4	12
71	FCI: an R-based algorithm for evaluating uncertainty of absolute real-time PCR quantification. BMC Bioinformatics, 2008, 9, 13.	1.2	11
72	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2011, 125, 855-860.	1.1	11

#	Article	IF	Citations
73	X chromosome inactivation pattern in BRCA gene mutation carriers. European Journal of Cancer, 2013, 49, 1136-1141.	1.3	11
74	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer, 2019, 118, 1-9.	1.3	11
75	Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. Breast Cancer Research and Treatment, 2000, 62, 135-139.	1.1	10
76	Biomarkers for Early Cancer Detection – Methodological Aspects. Breast Care, 2010, 5, 62-65.	0.8	10
77	Sequencing Analysis of SLX4/FANCP Gene in Italian Familial Breast Cancer Cases. PLoS ONE, 2012, 7, e31038.	1.1	10
78	Methylation status in patients with early stage colon cancer: A new prognostic marker?. International Journal of Cancer, 2012, 130, 488-489.	2.3	10
79	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541984640.	0.8	10
80	Reliability and Accuracy in Reporting CIN in 14 Laboratories. Acta Cytologica, 1998, 42, 1370-1376.	0.7	9
81	External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale. Journal of Experimental and Clinical Cancer Research, 2013, 32, 58.	3.5	9
82	High-dose-rate brachytherapy for high-grade vaginal intraepithelial neoplasia: a dosimetric analysis. Journal of Contemporary Brachytherapy, 2019, 11, 146-151.	0.4	9
83	Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse. Cancer Gene Therapy, 2021, 28, 1016-1024.	2.2	9
84	Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group. Annals of Oncology, 2002, 13, 1049-1058.	0.6	8
85	Association between CASP8 –652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE, 2014, 9, e85538.	1.1	8
86	A normalization strategy for the analysis of plasma microRNA qPCR data in colorectal cancer. International Journal of Cancer, 2014, 134, 2016-2018.	2.3	8
87	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2015, 44, 734-745.	1.4	8
88	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers, 2021, 13, 2433.	1.7	8
89	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. Cancer Prevention Research, 2021, 14, 963-972.	0.7	8
90	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8

#	Article	IF	CITATIONS
91	Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. Cancers, 2021, 13, 532.	1.7	8
92	Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards. Oncology Reports, 2010, 23, 853-60.	1.2	8
93	Reproducibility in the diagnosis of needle core biopsies of nonâ€palpable breast lesions: an international study using virtual slides published on the worldâ€wide web. Histopathology, 2010, 56, 720-726.	1.6	7
94	Assessing the Clinical Relevance of Oncogenic Pathways in Neoadjuvant Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1912-1915.	0.8	7
95	Combining qualitative and quantitative imaging evaluation for the assessment of genomic DNA integrity: The SPIDIA experience. Analytical Biochemistry, 2015, 479, 60-62.	1.1	7
96	The focus on sample quality: Influence of colon tissue collection on reliability of qPCR data. Scientific Reports, 2016, 6, 29023.	1.6	7
97	Shortâ€ŧerm and longâ€ŧerm outcomes after preventive surgery in adolescent patients with familial adenomatous polyposis. Pediatric Blood and Cancer, 2020, 67, e28110.	0.8	7
98	Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study. Cancers, 2022, 14, 298.	1.7	7
99	The Need for a Quality Control of the Whole Process of Immunohistochemistry Human Epidermal Growth Factor Receptor 2/ <i>neu</i> Netermination: A United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers Pilot Experience. Journal of Clinical Oncology, 2007, 25, e27-e28.	0.8	6
100	A BRCA1 promoter variant (rs11655505) and breast cancer risk. Journal of Medical Genetics, 2010, 47, 268-270.	1.5	6
101	A combination of extracellular matrix―and interferonâ€associated signatures identifies highâ€grade breast cancers with poor prognosis. Molecular Oncology, 2021, 15, 1345-1357.	2.1	6
102	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoidâ€type fibromatosis. Cancer Medicine, 2021, 10, 4356-4365.	1.3	6
103	Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. Cancers, 2021, 13, 4028.	1.7	6
104	Confidence interval estimation for DNA and mRNA concentration by real-time PCR: A new environment for an old theorem. International Journal of Biological Markers, 2004, 19, 76-79.	0.7	6
105	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. International Journal of Biological Markers, 2009, 24, 119-129.	0.7	6
106	What if the future of HER2â€positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine, 2022, 11, 332-339.	1.3	6
107	Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases. Nutrients, 2019, 11, 1020.	1.7	5
108	Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931 Journal of Clinical Oncology, 2018, 36, 11518-11518.	0.8	5

#	Article	IF	CITATIONS
109	Evaluation of Residual Cellularity and Proliferation on Preoperatively Treated Breast Cancer: A Comparison between Image Analysis and Light Microscopy Analysis. Analytical Cellular Pathology, 1998, 16, 83-93.	2.1	4
110	The Integrated Oncology Program of the Italian Ministry of Health. International Journal of Biological Markers, 2009, 24, 119-129.	0.7	4
111	Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients. Human Pathology, 2016, 47, 157-158.	1.1	4
112	Retrospective study of late radiation-induced damages after focal radiotherapy for childhood brain tumors. PLoS ONE, 2021, 16, e0247748.	1.1	4
113	Confidential enquiry into avoidable vehicle accident deaths in the province of Modena, Italy. European Journal of Epidemiology, 2000, 16, 67-74.	2.5	3
114	Androgen Receptor CAG Repeat Length and Estrogen Receptor Status in Postmenopausal Breast Cancer Prognosis. International Journal of Biological Markers, 2015, 30, 418-424.	0.7	3
115	Data and performances evaluation of the SPIDIA-DNA Pan-European External Quality Assessment: 2nd SPIDIA-DNA laboratory report. Data in Brief, 2016, 6, 980-984.	0.5	3
116	How Does the Display Luminance Level Affect Detectability of Breast Microcalcifications and Spiculated Lesions in Digital Breast Tomosynthesis (DBT) Images?. Academic Radiology, 2017, 24, 795-801.	1.3	3
117	The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative chemotherapy in a randomised controlled trial (RCT) Journal of Clinical Oncology, 2017, 35, 11016-11016.	0.8	3
118	External quality assessment schemes for real-time PCR: a statistical procedure to corrective actions. Clinical Chemistry and Laboratory Medicine, 2008, 46, 717-21.	1.4	2
119	Moving from Discovery to Validation in Circulating microRNA Research. International Journal of Biological Markers, 2015, 30, 258-261.	0.7	2
120	Comment on â€~Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'—Methodological challenges in combining miRNAs as circulating biomarkers. British Journal of Cancer, 2016, 114, e5-e5.	2.9	2
121	Methodological and statistical issues in developing an External Quality Assessment scheme in laboratory medicine: Focus on biomarker research. New Biotechnology, 2019, 52, 54-59.	2.4	2
122	SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region. Cancers, 2021, 13, 1035.	1.7	2
123	Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Manâ,,¢ probes. Clinical Chemistry and Laboratory Medicine, 2006, 44, 18-22.	1.4	1
124	Breast pathology guideline implementation in low―and middle―ncome countries. Cancer, 2009, 115, 5607-5607.	2.0	1
125	Tissue microarrays for immunohistochemical determination of oncological biomarkers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 353-354.	1.4	1
126	Different pixel pitch and maximum luminance of medical grade displays may result in different evaluations of digital radiography images. Radiologia Medica, 2018, 123, 586-592.	4.7	1

#	Article	IF	Citations
127	Workflow for Circulating miRNA Identification and Development in Cancer Research: Methodological Considerations., 2018,, 103-117.		1
128	Skip pattern approach toward the early access of innovative anticancer drugs. ESMO Open, 2021, 6, 100227.	2.0	1
129	Hereditary colorectal cancer syndromes and the COVID-19 pandemic: results from a survey conducted in patients enrolled in a dedicated registry. Quality of Life Research, 2021, , 1.	1.5	1
130	Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial Journal of Clinical Oncology, 2016, 34, 11044-11044.	0.8	1
131	Contrast-enhanced digital mammography and magnetic resonance imaging: reproducibility compared to pathologic anatomy. Tumori, 2022, 108, 563-571.	0.6	1
132	Research Trends for Early Cancer Biomarker Detection in Italy: An Integrated Program in Oncology (PIO) Survey. Tumori, 2010, 96, 721-725.	0.6	0
133	Comment to "Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson's disease― Digestive and Liver Disease, 2013, 45, 265.	0.4	0
134	\hat{l}° and \hat{l} » urine free light chains: a new method for quantification. Tumori, 2020, 106, 457-463.	0.6	0
135	Abstract 4038: Identification of microRNAs involved in colorectal cancer progression. , 2010, , .		0
136	Abstract 1874: Investigation of the cerebrospinal fluid proteome from central nervous system pediatric tumors using bait loaded hydrogel nanoparticles and mass spectrometry. , 2014, , .		0
137	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group Journal of Clinical Oncology, 2016, 34, 11045-11045.	0.8	O
138	Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU Journal of Clinical Oncology, 2018, 36, 11558-11558.	0.8	0
139	Research trends for early cancer biomarker detection in Italy: an integrated program in oncology (PIO) survey. Tumori, 2010, 96, 721-5.	0.6	0
140	Exploring the association with disease recurrence of miRNAs predictive of colorectal cancer. International Journal of Biological Markers, 2022, 37, 102-109.	0.7	0
141	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. Vaccines, 2022, 10, 734.	2.1	0
142	Reply to Serrano et al. Comment on "Colletti et al. Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study. Cancers 2022, 14, 298â€. Cancers, 2022, 14, 3241.	1.7	0